|
nasdaq:aveo
|
54167
|
Apr 21st, 2024 12:00AM
|
AVEO Oncology
|
20K
|
190.00
|
Open
|
|
Apr 20th, 2024 10:59PM
|
Apr 20th, 2024 10:59PM
|
AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.
|
Open
|
Oncology
|
Open
|
30 Winter St
|
Boston
|
Massachusetts
|
US
|
02108
|
|
AVEO Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:aveo
|
54167
|
Apr 20th, 2024 12:00AM
|
AVEO Oncology
|
20K
|
190.00
|
Open
|
|
Apr 19th, 2024 10:58PM
|
Apr 20th, 2024 04:37PM
|
AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.
|
Open
|
Oncology
|
Open
|
30 Winter St
|
Boston
|
Massachusetts
|
US
|
02108
|
|
AVEO Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:aveo
|
54167
|
Apr 19th, 2024 12:00AM
|
AVEO Oncology
|
20K
|
190.00
|
Open
|
|
Apr 18th, 2024 11:05PM
|
Apr 18th, 2024 11:05PM
|
AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.
|
Open
|
Oncology
|
Open
|
30 Winter St
|
Boston
|
Massachusetts
|
US
|
02108
|
|
AVEO Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:aveo
|
54167
|
Apr 18th, 2024 12:00AM
|
AVEO Oncology
|
20K
|
190.00
|
Open
|
|
Apr 17th, 2024 11:03PM
|
Apr 18th, 2024 05:56PM
|
AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.
|
Open
|
Oncology
|
Open
|
30 Winter St
|
Boston
|
Massachusetts
|
US
|
02108
|
|
AVEO Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:aveo
|
54167
|
Apr 17th, 2024 12:00AM
|
AVEO Oncology
|
20K
|
190.00
|
Open
|
|
Apr 16th, 2024 10:48PM
|
Apr 17th, 2024 02:20PM
|
AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.
|
Open
|
Oncology
|
Open
|
30 Winter St
|
Boston
|
Massachusetts
|
US
|
02108
|
|
AVEO Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:aveo
|
54167
|
Apr 16th, 2024 12:00AM
|
AVEO Oncology
|
20K
|
190.00
|
Open
|
|
Apr 15th, 2024 10:44PM
|
Apr 16th, 2024 10:37AM
|
AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.
|
Open
|
Oncology
|
Open
|
30 Winter St
|
Boston
|
Massachusetts
|
US
|
02108
|
|
AVEO Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:aveo
|
54167
|
Apr 15th, 2024 12:00AM
|
AVEO Oncology
|
20K
|
190.00
|
Open
|
|
Apr 14th, 2024 10:45PM
|
Apr 15th, 2024 04:18PM
|
AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.
|
Open
|
Oncology
|
Open
|
30 Winter St
|
Boston
|
Massachusetts
|
US
|
02108
|
|
AVEO Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:aveo
|
54167
|
Apr 14th, 2024 12:00AM
|
AVEO Oncology
|
20K
|
191.00
|
Open
|
|
Apr 13th, 2024 10:39PM
|
Apr 13th, 2024 10:39PM
|
AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.
|
Open
|
Oncology
|
Open
|
30 Winter St
|
Boston
|
Massachusetts
|
US
|
02108
|
|
AVEO Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:aveo
|
54167
|
Apr 13th, 2024 12:00AM
|
AVEO Oncology
|
20K
|
191.00
|
Open
|
|
Apr 12th, 2024 10:29PM
|
Apr 13th, 2024 11:05AM
|
AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.
|
Open
|
Oncology
|
Open
|
30 Winter St
|
Boston
|
Massachusetts
|
US
|
02108
|
|
AVEO Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:aveo
|
54167
|
Apr 12th, 2024 12:00AM
|
AVEO Oncology
|
20K
|
191.00
|
Open
|
|
Apr 11th, 2024 10:33PM
|
Apr 12th, 2024 08:00AM
|
AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.
|
Open
|
Oncology
|
Open
|
30 Winter St
|
Boston
|
Massachusetts
|
US
|
02108
|
|
AVEO Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|